Cargando…

Chronic Abdominal Pain in IBD Research Initiative: Unraveling Biological Mechanisms and Patient Heterogeneity to Personalize Treatment and Improve Clinical Outcomes

Detalles Bibliográficos
Autores principales:	Hurtado-Lorenzo, Andrés, Honig, Gerard, Weaver, Sarah Alandra, Larkin, Paul B, Heller, Caren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802354/ https://www.ncbi.nlm.nih.gov/pubmed/36776666 http://dx.doi.org/10.1093/crocol/otab034

Ejemplares similares

Precision Nutrition Initiative: Toward Personalized Diet Recommendations for Patients With Inflammatory Bowel Diseases
por: Hurtado-Lorenzo, Andrés, et al.
Publicado: (2020)

Research-Based Product Innovation to Address Critical Unmet Needs of Patients with Inflammatory Bowel Diseases
por: Honig, Gerard, et al.
Publicado: (2021)

Dissecting the Heterogeneity in T-Cell Mediated Inflammation in IBD
por: Tindemans, Irma, et al.
Publicado: (2020)

Addressing Mental Health in Persons with IBD
por: Bernstein, Charles N
Publicado: (2018)

The gut microbiota heterogeneity and assembly changes associated with the IBD
por: Sun, Yang, et al.
Publicado: (2019)

Personalized management of IBD; is there any practical approach?
por: Norouzinia, Mohsen, et al.
Publicado: (2015)

Patients with Inflammatory Bowel Disease Have Heterogeneous Treatment Preferences That Are Largely Determined by the Avoidance of Abdominal Pain and Side Effects [P-POWER IBD Study]
por: Louis, Edouard, et al.
Publicado: (2022)

Advances in single-cell metabolomics to unravel cellular heterogeneity in plant biology
por: Pandian, Kanchana, et al.
Publicado: (2023)

Prognostic Factors of Biologic Therapy in Pediatric IBD
por: Buczyńska, Anna, et al.
Publicado: (2022)

Editorial: Personalizing Treatment in IBD: Hype or Reality in 2020?
por: Gomollón, Fernando, et al.
Publicado: (2021)

Use, Durability, and Risks for Discontinuation of Initial and Subsequent Biologics in a Large Pediatric-Onset IBD Cohort
por: Kaplan, Jess L., et al.
Publicado: (2023)

Unraveling heterogeneous susceptibility and the evolution of breast cancer using a systems biology approach
por: Castellanos-Martín, Andrés, et al.
Publicado: (2015)

Association of IBD specific treatment and prevalence of pain in the Swiss IBD cohort study
por: Bon, Lorenz, et al.
Publicado: (2019)

Nutritional Assessment in Inflammatory Bowel Disease (IBD)—Development of the Groningen IBD Nutritional Questionnaires (GINQ)
por: Peters, Vera, et al.
Publicado: (2019)

Intercontinental Gut Microbiome Variances in IBD
por: Mayorga, Luis, et al.
Publicado: (2022)

Unraveling Macrophage Heterogeneity in Erythroblastic Islands
por: Seu, Katie Giger, et al.
Publicado: (2017)

Subclinical Pulmonary Involvement in Active IBD Responds to Biologic Therapy
por: Ellrichmann, M, et al.
Publicado: (2021)

Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient
por: Nones, Rodrigo Bremer, et al.
Publicado: (2021)

Weight and BMI Patterns in a Biologicals-Treated IBD Cohort
por: Kaazan, P., et al.
Publicado: (2022)

A74 URGENCY FOR BOWEL MOVEMENTS IS A HIGHLY DISCRIMINATORY SYMPTOM FOR ACTIVE DISEASE IN PERSONS WITH IBD (THE MANITOBA LIVING WITH IBD STUDY)
por: Kulyk, A, et al.
Publicado: (2023)

Are Patient Self-reported Healthcare Utilization Data Reliable in Persons With IBD?
por: El-Matary, Wael
Publicado: (2021)

Bowel Location Rather Than Disease Subtype Dominates Transcriptomic Heterogeneity in Pediatric IBD
por: Venkateswaran, Suresh, et al.
Publicado: (2018)

Bridges to excellence quality indicators in inflammatory bowel disease (IBD): differences between IBD and non-IBD gastroenterologists
por: Bilal, Mohammad, et al.
Publicado: (2017)

Lymphoma Heterogeneity Unraveled by Single-Cell Transcriptomics
por: Ysebaert, Loic, et al.
Publicado: (2021)

Unravelling the Heterogeneity of Non Insulin Dependent Diabetes
por: Pearson, Ewan R, et al.
Publicado: (2000)

The Interplay Between Use of Biological Therapies, Psychological State, and the Microbiome in IBD
por: Tavakoli, Paris, et al.
Publicado: (2022)

Mo1087: MALADAPTIVE BEHAVIORS IN PERSONS WITH IBD DURING THE COVID-19 PANDEMIC
por: Shaffer, Seth R., et al.
Publicado: (2022)

IBD LIVE Case Series–Case 2: Previous Cancer in a Patient with Crohn's Disease: Is It Appropriate to Use Biologics and Immunosuppressants for IBD Treatment?
por: Le, Peter N., et al.
Publicado: (2015)

COVID-19 in IBD: The experience of a single tertiary IBD center
por: Rizzello, Fernando, et al.
Publicado: (2021)

Distinct transcriptional signatures in purified circulating immune cells drive heterogeneity in disease location in IBD
por: Verstockt, Bram, et al.
Publicado: (2023)

Unraveling Tumor Heterogeneity by Using DNA Barcoding Technologies to Develop Personalized Treatment Strategies in Advanced-Stage PDAC
por: Dujardin, Philip, et al.
Publicado: (2021)

Editorial: Unravelling T. cruzi Biology
por: Taylor, Martin Craig, et al.
Publicado: (2020)

Zebrafish model for IBD
Publicado: (2011)

IBD considerations in spondyloarthritis
por: Di Jiang, Caroline, et al.
Publicado: (2020)

The Impact of PPARγ Genetic Variants on IBD Susceptibility and IBD Disease Course
por: Mwinyi, Jessica, et al.
Publicado: (2012)

Risk of Adverse Pregnancy Outcomes for Women with IBD in an Expert IBD Antenatal Clinic
por: Lever, Gillian, et al.
Publicado: (2022)

Analysis of intratumor heterogeneity unravels lung cancer evolution
por: de Bruin, Elza C, et al.
Publicado: (2015)

Deep learning for unravelling features of heterogeneous ice nucleation
por: Valeriani, Chantal
Publicado: (2022)

Optimizing biologic treatment in IBD: objective measures, but when, how and how often?
por: Ben-Horin, Shomron, et al.
Publicado: (2015)

The Usefulness of Serum Vitamin D Levels in the Assessment of IBD Activity and Response to Biologics
por: Valvano, Marco, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ua2o7rju0n68kvcg4jbg6843an